ArticlemedRxiv : the preprint server for health sciences2025
Evaluating the biomedical and behavioural drivers of HIV-1 incidence decline in adolescent girls and young women in Uganda: A mathematical modelling study.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
22 authors.
Funding
Abstract
Background: Recent declines in HIV incidence among adolescent girls and young women (AGYW) in Africa are often attributed to the expansion of biomedical interventions such as antiretroviral therapy and voluntary medical male circumcision. However, changes in sexual behaviour may also play a critical role. Understanding the relative contributions of these factors is essential for developing strategies to sustain and further reduce HIV transmission. Methods: We conducted a mathematical modelling study of data from the Rakai Community Cohort Study (RCCS), an open, population-based cohort of 15- to 49-year-olds in 30 communities in Rakai, Uganda, to investigate the biomedical and behavioural drivers of HIV incidence decline in AGYW (15-24 years of age). We estimated changes in the HIV incidence rate between 2000-2019 using retrospective cohort data to validate our modelled incidence estimates. We ran modelled counterfactual scenarios to quantify the independent and combined effects (cumulative infections averted and difference in incidence rates) of antiretroviral therapy (ART), voluntary medical male circumcision (VMMC), and delays in age of first sex (AFS) over historical (between 2000-2020) and projected (between 2000-2050) time horizons. Findings: Incidence in women 15-24 years of age declined by 83% between 2000-2019 (from 1.72 per 100 person-years in 2000 to 0.30 per 100 person-years in 2019), the largest reduction in incidence of all age groups of women. Increasing AFS over the last two decades (by 3 years in women and 2 years in men) was the largest contributor to incidence decline in women 15-19 years of age, averting 17% of cumulative infections between 2000-2020 and 37% between 2000-2050. Incidence in 15-19-year-old women was 69% lower in 2020 and 75% lower in 2050 compared to counterfactual scenarios without changes in AFS. ART scale-up contributed the most to incidence declines among women 20-24 years of age, averting 13% of infections between 2000-2020 and 43% of infections between 2000-2050. VMMC averted < 5% of infections in 15-24-year-olds to-date, with larger reductions in incidence between 2000-2050 in both 15-19 year-olds (13% reduction in cumulative infections) and 20-24 year-olds (22% of cumulative infections). ART, VMMC, and increasing AFS acted additively to reduce HIV incidence in AGYW, with little redundancy when combined. Interpretation: Our results provide strong support for maintaining both the protective changes in sexual behaviours and effective biomedical interventions to sustain continued reductions in HIV incidence among AGYW.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.